MTOR and gastric cancer: MiR-107 downregulates the expression of high mobility group A2 (HMGA2) and inhibits the HMGA2/mammalian target of the rapamycin (mTOR)/P-glycoprotein 1 (P-gp) pathway in resistant GC cells, effectively reducing their ability to proliferate [158].